Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 101

1.

Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.

Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao JH, Lee KS, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S.

J Interferon Cytokine Res. 2016 Nov;36(11):635-643. Epub 2016 Jun 21.

PMID:
27327078
2.

[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].

Lorcy S, Gaudy-Marqueste C, Botta D, Portal I, Quiles N, Oulies V, Mancini J, Grob JJ, Richard MA.

Ann Dermatol Venereol. 2016 May;143(5):336-46. doi: 10.1016/j.annder.2016.02.028. Epub 2016 May 6. French.

PMID:
27161648
3.

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.

Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S.

World J Gastroenterol. 2016 Mar 28;22(12):3418-31. doi: 10.3748/wjg.v22.i12.3418.

4.

Drug-Induced Subacute Cutaneous Lupus Erythematosus in a Patient Receiving Therapy for Chronic Hepatitis C.

Reyes HA, Cativo EH, Sy AM.

Am J Ther. 2016 Nov/Dec;23(6):e1965-e1967.

PMID:
26539906
5.

Cutaneous Eruption due to Telaprevir.

Falcão EM, Trope BM, Godinho MM, Carneiro LH, de Araujo-Neto JM, Nogueira CA, Ramos-E-Silva M.

Case Rep Dermatol. 2015 Sep 29;7(3):253-62. doi: 10.1159/000439264. eCollection 2015 Sep-Dec.

6.

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.

Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM; HCV-TARGET Study Group.

Gastroenterology. 2016 Feb;150(2):419-29. doi: 10.1053/j.gastro.2015.10.013. Epub 2015 Oct 21.

7.

Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.

Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, Zakharova N, Rivero A, Durant J, Ortega-Gonzalez E, Lathouwers E, Janssen K, Ouwerkerk-Mahadevan S, Witek J, González-García J.

J Antimicrob Chemother. 2016 Jan;71(1):244-50. doi: 10.1093/jac/dkv323. Epub 2015 Oct 19.

PMID:
26483516
8.

Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme.

Gori A, Doroana M, Chernova O, Rockstroh JK, Banhegyi D, Bergin C, Verucchi G, Liu C, DeMasi R, Hadacek B, Nelson M.

J Infect. 2015 Dec;71(6):675-82. doi: 10.1016/j.jinf.2015.09.013. Epub 2015 Sep 28.

PMID:
26416471
9.

Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.

Litwin AH, Soloway IJ, Cockerham-Colas L, Reynoso S, Heo M, Tenore C, Roose RJ.

Int J Drug Policy. 2015 Oct;26(10):1014-9. doi: 10.1016/j.drugpo.2015.08.008. Epub 2015 Aug 20.

10.

Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection.

Naqvi A, Giordanengo V, Dunais B, de Salvador-Guillouet F, Perbost I, Durant J, Pugliese P, Joulié A, Roger PM, Rosenthal E.

World J Hepatol. 2015 Aug 28;7(18):2177-83. doi: 10.4254/wjh.v7.i18.2177.

11.

Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.

Kumada H, Suzuki F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, Fujiyama S, Ito T, Itoh Y, Tamura E, Ueki T, Ishikawa H, Hu W, McPhee F, Linaberry M, Hughes E.

J Gastroenterol Hepatol. 2016 Jan;31(1):14-22. doi: 10.1111/jgh.13073.

PMID:
26252875
12.

Retreatment of Chronic Hepatitis C Infection with Telaprevir: Preliminary Results in Turkey.

Aygen B, Yıldız O, Akhan S, Çelen MK, Ural O, Koruk ST, Köse Ş, Korkmaz F, Kuruüzüm Z, Tuna N, Taheri S, Sayan M, Demir NA, Sümer Ş, Altınok ES.

Balkan Med J. 2015 Jul;32(3):266-72. doi: 10.5152/balkanmedj.2015.15366. Epub 2015 Jul 1.

13.

Costs and Resource Utilization Associated With Anemia and Rash in Chronic Hepatitis C Patients Treated With Direct-Acting Antiviral Agents in the United States.

Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.

Clin Ther. 2015 Aug;37(8):1713-25.e3. doi: 10.1016/j.clinthera.2015.05.503. Epub 2015 Jun 22.

PMID:
26111918
14.

Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.

Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J.

J Gastroenterol Hepatol. 2015 Dec;30(12):1759-67. doi: 10.1111/jgh.13016.

PMID:
26095167
15.

Telaprevir-induced moderate cutaneous eruptions associated with HHV-6 reactivation.

Broccolo F, Ciccarese G, Agnoletti AF, Bruzzone L, Calamaro P, Zappacosta R, Oggioni M, Parodi A, Drago F.

J Med Virol. 2015 Dec;87(12):1985-6. doi: 10.1002/jmv.24269. Epub 2015 Jun 2. No abstract available.

PMID:
25980458
16.

Similar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV Therapy.

Soria A, Limonta S, Leone S, Muscatello A, Squillace N, Bandera A, Gori A.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):e37-40. doi: 10.1097/QAI.0000000000000541. No abstract available.

PMID:
25942467
17.

A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.

Taieb V, Pacou M, Ho S, Pettré S, Van Sanden S, Pisini M, Ustianowski A, Mehnert A.

J Med Econ. 2015;18(10):787-96. doi: 10.3111/13696998.2015.1046880. Epub 2015 May 26. Review.

PMID:
25934147
18.

Telaprevir experience from Turkey.

Komur S, Kurtaran B, Inal AS, Pullukcu H, Ulu A, Kuscu F, Yamazhan T, Tasova Y, Aksu HS.

Hepat Mon. 2015 Feb 18;15(2):e25639. doi: 10.5812/hepatmon.25639. eCollection 2015 Feb.

19.

Dermatologic adverse events of protease inhibitor-based combination therapy in patients with chronic hepatitis C.

Kłujszo E, Parcheta P, Zarębska-Michaluk D, Ochwanowska E, Witkowska A, Rakowska A, Rudnicka L, Kryczka W.

J Dermatol Case Rep. 2014 Dec 31;8(4):95-102. doi: 10.3315/jdcr.2014.1183. eCollection 2014 Dec 31.

20.

Drug-induced liver injury in a chronic hepatitis C patient treated by peginterferon, ribavirin and simeprevir.

Okajima A, Yamaguchi K, Taketani H, Hara T, Ishiba H, Seko Y, Nishimura T, Nishikawa T, Fujii H, Moriguchi M, Mitsuyoshi H, Sumida Y, Yasui K, Minami M, Itoh Y.

Hepatol Res. 2015 Oct;45(10):E156-60. doi: 10.1111/hepr.12477. Epub 2015 Feb 18.

PMID:
25581068

Supplemental Content

Loading ...
Support Center